$1.5M in Q4 added to their earlier $3.8M will give 'em fiscal 2017 revenues of $5.3M which will represent a dramatic YOY increase on their $2M 2016 revs and put them on track for somewhere between $6M and $10M in 2018 revenues.
A lot of their 2018 revenue potential is going to depend on whether or not MNK can grow Seroquel XR sales and how soon the FDA finally gets around to granting approvals on Pristiq or Lamictal.
The wildcard is potential partnerships or licensing deals. They have recently provided strong hints that something may be brewing in China and internationally on the potential licensing deal fronts.
And they do say they anticipate launching Phase III trials on their Regabatin NDA sometime in the back half of this year...which would seem to allude to a potential Regabatin partnership coming on that front in the back half of 2018 as a distinct possibility.
No matter what with the CAT 2 & 3 HAP studies expected to launch next month on their Oxy candidate and human trials expected to launch on PODRAS by/b4 June 30th, 2018's shaping up to provide some positives to combat the market apathy of the past 6 months.
Hoping to see earnings arrive with some more projections and possible update on the oral and nasal studies front.
Wimus, indeed big possibility. What i ment was that it should be more clear how they will fund next quarter. Offering? enough income? ATM? I'm sure questions about the cash balance and how to fund further operations/test/etc will be asked at the conference call! So hopefully it will be much more clear. I wait for some improvements to get in again AND i want to see positive numbers/earnings before buying this stock again. They promised already too much for too much time!
News 
Market Data 
Discover 
